Citations

Clear

7 citation(s) found for "Apovian, Caroline M".

A Multicenter Double-blind Randomized Sham-controlled Trial Assessing the EndoBarrier Duodenal-jejunal Bypass Liner for the Treatment of Poorly Controlled Type 2 Diabetes Mellitus With Concomitant Obesity
Thompson, Christopher C. , Jirapinyo, Pichamol , Brethauer, Stacy A., Shaheen, Nicholas J. , Sullivan, Shelby , Wilson, Erik B., Schulman, Allison R. , Butsch, W. Scott , Gersin, Keith S., Apovian, Caroline M., Schauer, Philip, McCarty, Thomas R. , Koch, Timothy R. , Dayyeh, Barham K. Abu

Mayo Clinic

Annals of Surgery | November 7, 2025 | Volume: 284 | Issue: 1 | Pages: 34-42

10.1097/sla.0000000000006974 | PMID 41199626 Get It

Objective: An endoscopically placed duodenal-jejunal bypass liner (DJBL) may provide a safe adjunctive therapy for those with poorly controlled type 2 diabetes mellitus (T2DM) and obesity. Background: Although some endoscopic therapies have been shown to improve glycemic indices secondary to weight loss, small bowel interventions may have direct metabolic effects. A meta-analysis of observational studies demonstrated reduction in HbA1c by 1.3% at 1 year after DJBL in patients with T2DM and obesity. Methods: This was a multicenter, double-blind, randomized, sham-controlled trial comparing DJBL to sham procedure with medical management and lifestyle modification. Primary endpoints included mean difference in changes in HbA1c at 12 months between arms, and device-related serious adverse events (SAEs). Secondary endpoints included percent total weight loss (%TWL) and subjects achieving HbA1c≤7% and TWL≥5% at 12 months. Results: Three hundred twenty subjects were randomized to DJBL (n=212) and sham (n=108). Baseline HbA1c and BMI were 8.79±0.92% and 38.45±5.75 kg/m 2 . On modified intent-to-treat analysis, change in HbA1c at 12 months was −1.10±1.45% and −0.28±1.54% for DJBL and sham groups, respectively ( P =0.0004). Rate of device-related SAEs was 9.4% including intolerance (3.7%), hemorrhage (2.8%), and hepatic abscess (2.3% stopping study early). At 12 months, DJBL group experienced greater weight loss compared with sham (7.7±9.6% TWL and 2.1±5.4% TWL, respectively; P <0.0001), with significantly more patients achieving HbA1c ≤ 7% (28.3% vs. 9.4%; P <0.0003) and TWL ≥ 5% (60.4% vs. 21.3%; P <0.0001). Conclusions: DJBL met primary glycemic control efficacy and primary safety endpoints, while providing clinically significant weight loss, and comorbidity improvement.
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Woolf, Emily K. , Diktas, Hanim E. , Acosta, Andrés , Apolzan, John W. , Ard, Jamy D. , Boyle, Kristen E. , Katzmarzyk, Peter T. , Nicastro, Holly L. , Redman, Leanne M. , Stephens, Jacqueline M. , Martin, Corby K. , Katzmarzyk, Peter T , Phelan, Suzanne , Redman, Leanne , Roe, Brian E , Stephens, Jacqueline M , Tate, Deborah F , Apovian, Caroline M , Martin, Corby K , Acosta, Andres , Gilbert, Jack A. , Laurienti, Paul J. , Lobstein, Tim , Ordovás, José María , Ryan, Donna H. , Tate, Deborah F.

Mayo Clinic

Obesity | September 18, 2025 | Volume: 33 | Issue: 11 | Pages: 2029-2045

10.1002/oby.70015 | PMID 40964812 Get It

ABSTRACT Precision medicine approaches have gained attention for their potential to more effectively manage obesity by tailoring diagnosis and treatment strategies to individual characteristics, including genetic background, phenotypes, metabolic profiles, and environmental exposures. The current review evaluates the evidence for precision medicine in weight management by summarizing the proceedings of a Pennington Biomedical Scientific Symposium titled “Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?” This review discusses the extent to which we can classify and predict obesity risk based on individual‐level factors; whether we have the diagnostic capability to prospectively identify people who will benefit most from specific interventions; whether prospective trials demonstrate superior prevention and treatment of obesity when precision approaches are applied; and whether evidence is sufficient to guide policy decisions. Expert opinions were presented on the current evidence of precision medicine for obesity to collectively evaluate key barriers and opportunities for implementation of precision approaches in clinical and public health settings.
Correction: American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity
Jirapinyo, Pichamol , Hadefi, Alia , Huberty, Vincent, Sullivan, Shelby , Thompson, Christopher C. , Patai, Árpád V. , Pannala, Rahul , Goelder, Stefan, Kushnir, Vladimir , Apovian, Caroline M., Chapman, Christopher G., Davidson, Paul , Kumbhari, Vivek , Esker, Janelle, Hucl, Tomáš , Schulman, Allison R. , Zelber‐Sagi, Shira , Bain, Paul , Huberty, Vincent, Barthet, Marc , Boškoski, Ivo , Donatelli, Gianfranco , Hayee, Bu , Pryor, Aurora Dawn , Maselli, Roberta , Pattou, François , Durieux, Valérie , Τriantafyllou, Κonstantinos , Thosani, Nirav C

Mayo Clinic

Endoscopy | July 28, 2025 | Volume: 57 | Issue: 09 | Pages: C12-C12

10.1055/a-2651-9666 | PMID 40720956 Get It

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
Cusi, Kenneth , Bardsley, Joan K. , Isaacs, Scott , Kanwal, Fasiha , Richardson, Caroline R., Roden, Michael, Younossi, Zobair M. , Bajaj, Mandeep , Bajaj, Mandeep , Abdelmalek, Manal F. , Bannuru, Raveendhara R , Apovian, Caroline M , Balapattabi, Kirthikaa , Bannuru, Raveendhara R. , Barb, Diana , Beverly, Elizabeth Ann , Corbin, Karen D. , ElSayed, Nuha A. , Pekas, Elizabeth J. , Richardson, Caroline R., Roden, Michael , Sanyal, Arun J. , Shubrook, Jay H

Mayo Clinic

Diabetes Care | May 28, 2025 | Volume: 48 | Issue: 7 | Pages: 1057-1082

10.2337/dci24-0094 | PMID 40434108 Get It

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes, especially when associated with obesity). Liver health has not been at the forefront of complications tracked for disease prevention, as traditionally done for diabetic retinopathy, nephropathy, or neuropathy. However, liver steatosis affects approximately two out of three people with type 2 diabetes and places them at an increased risk for metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma (HCC), and overall liver-related mortality. MASLD is also associated with extrahepatic cancers, atherosclerotic cardiovascular disease, and progression from prediabetes to type 2 diabetes and negatively impacts health-related quality of life. However, most individuals and their health care professionals remain unaware of the severe hepatic or extrahepatic health risks associated with MASLD and the need for early identification. In recognition of this knowledge gap and the rising prevalence of MASLD, this consensus report is a call to action to screen for liver fibrosis and risk stratify people with prediabetes or type 2 diabetes, in particular if obesity is also present. This consensus report explains the rationale for the recent MASLD nomenclature change, how to best risk stratify, current treatment and long-term monitoring options, the value of an interprofessional approach to disease management, and the impact of alcohol intake on liver health. More awareness about the health risks associated with MASLD and broad adoption of screening for liver fibrosis as a new standard of care hold promise for a future without cirrhosis for people with prediabetes and type 2 diabetes.
American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity
Jirapinyo, Pichamol , Hadefi, Alia , Sullivan, Shelby , Thompson, Christopher C. , Patai, Árpád V. , Pannala, Rahul , Goelder, Stefan, Kushnir, Vladimir , Apovian, Caroline M., Chapman, Christopher G., Davidson, Paul , Kumbhari, Vivek , Esker, Janelle, Hucl, Tomáš , Schulman, Allison R. , Zelber‐Sagi, Shira , Bain, Paul , Huberty, Vincent , Barthet, Marc , Boškoski, Ivo , Donatelli, Gianfranco , Hayee, Bu , Pryor, Aurora Dawn , Maselli, Roberta , Pattou, François , Durieux, Valérie , Τriantafyllou, Κonstantinos , Thosani, Nirav C

Mayo Clinic

Endoscopy | April 19, 2024 | Volume: 56 | Issue: 06 | Pages: 437-456

10.1055/a-2292-2494 | PMID 38641332 Get It

AbstractThis joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ≥30 kg/m2, or with a BMI of 27.0–29.9 kg/m2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.
Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology,
Apovian, Caroline M., Brethauer, Stacy A., Joffe, Aaron M. , Kushner, Robert F. , Lindquist, R R , Pessah‐Pollack, Rachel , Seger, Jennifer, Adams, Stephanie, Cleek, John B., Correa, Riccardo , Figaro, M. Kathleen, Flanders, Karen, Grams, Jayleen , Hurley, Daniel L. , Kothari, Shanu N. , Seger, Michael, Still, Christopher D. , Mechanick, Jeffrey I. , Garvey, William Timothy , Kim, Julie , Lindquist, Richard, Urman, Richard D , Seger, Michael V.

Mayo Clinic

Obesity | March 23, 2020 | Volume: 28 | Issue: 4 | Pages: No page available

10.1002/oby.22719 | PMID 32202076 Get It

Objective The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association of Clinical Endocrinologists (AACE), The Obesity Society (TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), Obesity Medicine Association (OMA), and American Society of Anesthesiologists (ASA) Boards of Directors in adherence with the AACE 2017 protocol for standardized production of CPGs, algorithms, and checklists. Methods Each recommendation was evaluated and updated based on new evidence from 2013 to the present and subjective factors provided by experts. Results New or updated topics in this CPG include: contextualization in an adiposity‐based chronic disease complications‐centric model, nuance‐based and algorithm/checklist‐assisted clinical decision‐making about procedure selection, novel bariatric procedures, enhanced recovery after bariatric surgery protocols, and logistical concerns (including cost factors) in the current health care arena. There are 85 numbered recommendations that have updated supporting evidence, of which 61 are revised and 12 are new. Noting that there can be multiple recommendation statements within a single numbered recommendation, there are 31 (13%) Grade A, 42 (17%) Grade B, 72 (29%) Grade C, and 101 (41%) Grade D recommendations. There are 858 citations, of which 81 (9.4%) are evidence level (EL) 1 (highest), 562 (65.5%) are EL 2, 72 (8.4%) are EL 3, and 143 (16.7%) are EL 4 (lowest). Conclusions Bariatric procedures remain a safe and effective intervention for higher‐risk patients with obesity. Clinical decision‐making should be evidence based within the context of a chronic disease. A team approach to perioperative care is mandatory, with special attention to nutritional and metabolic issues.
Sustained Weight Loss with Vagal Nerve Blockade but Not with Sham: 18-Month Results of the ReCharge Trial
Shikora, Scott A. , Wolfe, Bruce M. , Anvari, Mehran , Gibbons, Robert D. , Ikramuddin, Sayeed , Miller, Christopher J. , Knudson, Mark B., Tweden, Katherine S. , Sarr, Michael G. , Apovian, Caroline M , Sarwer, David B , Billington, Charles J.

Mayo Clinic

Journal of Obesity | July 12, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-8

10.1155/2015/365604 | PMID 26246907 Get It

Background/Objectives. Vagal block therapy (vBloc) is effective for moderate to severe obesity at one year.Subjects/Methods. The ReCharge trial is a double-blind, randomized controlled clinical trial of 239 participants with body mass index (BMI) of 40 to 45 kg/m or 35 to 40 kg/m with one or more obesity-related conditions. Interventions were implantation of either vBloc or Sham devices and weight management counseling. Mixed models assessed percent excess weight loss (%EWL) and total weight loss (%TWL) in intent-to-treat analyses. At 18 months, 142 (88%) vBloc and 64 (83%) Sham patients remained enrolled in the study.Results. 18-month weight loss was 23% EWL (8.8% TWL) for vBloc and 10% EWL (3.8% TWL) for Sham (P<0.0001). vBloc patients largely maintained 12-month weight loss of 26% EWL (9.7% TWL). Sham regained over 40% of the 17% EWL (6.4% TWL) by 18 months. Most weight regain preceded unblinding. Common adverse events of vBloc through 18 months were heartburn/dyspepsia and abdominal pain; 98% of events were reported as mild or moderate and 79% had resolved.Conclusions. Weight loss with vBloc was sustained through 18 months, while Sham regained weight between 12 and 18 months. vBloc is effective with a low rate of serious complications.